---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059734"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-05-13T10:35:21+00:00"
generated_at: "2026-05-13T10:42:10.706018+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Q1 net loss $3.3M ($0.22/sh); cash $46.5M; APR-1051 shows two partial responses

## Summary
- Cash and equivalents $46.5M as of Mar 31, 2026, up from $14.6M year-end 2025; runway into Q1 2028.
- Operating loss $3.4M for Q1 2026 vs $4.1M in Q1 2025; R&D expense fell to $1.6M from $2.5M.
- WEE1 inhibitor APR-1051: two partial responses observed; dose escalation ongoing; ASCO 2026 presentation on May 30.
- Oversubscribed $30M private placement closed Mar 31, 2026, led by Soleus Capital to expand APR-1051 enrollment.
- ATRN-119 (ATR inhibitor) monotherapy paused; evaluating combination approaches including with radiation.

## SEC filing metadata
- accession: 0001104659-26-059734
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-05-13T10:35:21+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/0001104659-26-059734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059734
- JSON: https://secwatch.observer/filing/0001104659-26-059734.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059734.txt

## Key facts
- Earnings Releases
  Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 13, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026, and provided an update on the Company’s operations for the same period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/0001104659-26-059734-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.